Recent Updates
Recently added Catalysts

an inactivated whole virion H5N1 vaccine, adjuvanted

Phase 1

Influenza | Monoclonal antibody | Infectious Disease |Sinovac Biotech, Ltd|Last Updated: Nov 9, 2007

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindUNCONTROLLED
Total Trials1
Total Enrollment120

FDA Designations

No designations recorded

Clinical trial landscape

an inactivated whole virion H5N1 vaccine, adjuvanted · 1 trial · 1 indication

Phase 1 1
NCT00356798Randomized, Double Blinded, Placebo Control Clinical Trial of Pandemic Influenza Inactive Vaccine on Healthy SubjectsInfluenza
COMPLETED120 Analytics
PHASE1COMPLETED
Randomized, Double Blinded, Placebo Control Clinical Trial of Pandemic Influenza Inactive Vaccine on Healthy Subjects
InfluenzaUnlock trial analytics

Study Endpoints

Primary Endpoints

To evaluate the safety of pandemic inactivated influenza vaccine by different does.

Secondary Endpoints

To evaluate the immunogenicity of pandemic inactivated influenza vaccine by different does.
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelFACTORIAL
PurposePREVENTION

Interventions

NameTypeDescription
an inactivated whole virion H5N1 vaccine, adjuvantedBIOLOGICAL -
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 60 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Males and females, age from 18 to 60 years old; * Able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process; * Able and willing to complete the informed consent process. Exclusion Criteria: * Woman who is breast-feeding or...

Countries:China
Unlock Eligibility Criteria